Catherine Novack
Stock Analyst at Jones Trading
(0.62)
# 2,686
Out of 4,479 analysts
8
Total ratings
25%
Success rate
-16.49%
Average return
Main Sectors:
Top Industries:
8 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGLS Regulus Therapeutics | Initiates: Buy | $8 | $1.76 | +354.55% | 1 | May 31, 2024 | |
| RZLT Rezolute | Initiates: Buy | $10 | $4.21 | +137.53% | 1 | Apr 18, 2024 | |
| FEMY Femasys | Maintains: Buy | $7 → $10 | $1.11 | +800.90% | 1 | Mar 20, 2024 | |
| CALC CalciMedica | Initiates: Buy | $22 | $4.01 | +448.63% | 1 | Feb 16, 2024 | |
| KZR Kezar Life Sciences | Downgrades: Hold | n/a | $0.57 | - | 1 | Oct 5, 2023 | |
| PPBT Purple Biotech | Initiates: Buy | $8 | $0.37 | +2,063.92% | 1 | Jul 21, 2023 | |
| OMGA Omega Therapeutics | Initiates: Buy | $11 | $2.07 | +431.40% | 1 | Mar 10, 2023 | |
| DARE Daré Bioscience | Initiates: Buy | $6 | $3.63 | +65.29% | 1 | Dec 1, 2022 |
Regulus Therapeutics
May 31, 2024
Initiates: Buy
Price Target: $8
Current: $1.76
Upside: +354.55%
Rezolute
Apr 18, 2024
Initiates: Buy
Price Target: $10
Current: $4.21
Upside: +137.53%
Femasys
Mar 20, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $1.11
Upside: +800.90%
CalciMedica
Feb 16, 2024
Initiates: Buy
Price Target: $22
Current: $4.01
Upside: +448.63%
Kezar Life Sciences
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.57
Upside: -
Purple Biotech
Jul 21, 2023
Initiates: Buy
Price Target: $8
Current: $0.37
Upside: +2,063.92%
Omega Therapeutics
Mar 10, 2023
Initiates: Buy
Price Target: $11
Current: $2.07
Upside: +431.40%
Daré Bioscience
Dec 1, 2022
Initiates: Buy
Price Target: $6
Current: $3.63
Upside: +65.29%